secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001493152-26-009526
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte restructures Liora acquisition; issues 700k shares, $440k cash, Bitcoin/Ethereum for 80% stake
--------------------------------------------------------------------------------

- Amended Share Exchange consolidates prior transactions; Lixte acquires 800 of 1,000 Liora shares (80%).
- Consideration includes 700,000 common shares, $440,000 cash, 10.56 Bitcoin and 300 Ethereum to Orbit Capital.
- Liora holds assets for LIGHT proton-based radiotherapy system acquired from Advanced Oncotherapy PLC.
- Orbit retains 20% of Liora after terminating original royalty agreement and Series C Preferred exchange.
- Agreement effective November 21, 2025, executed March 6, 2026 to unify multiple transaction documents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315226009526/0001493152-26-009526-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315226009526/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009526

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer